Where Is Novo Nordisk Corporate Office Headquarters
Novo Nordisk Headquarters Address and Contact
-
Address: 800 Scudders Mill Rd, Plainsboro Township, NJ 08536, United States
-
-
-
-
-
-
Novo Nordisk Headquarters Location & Directions
How to Contact Novo Nordisk Corporate Office
Do you need to make some special orders or do you need to make clarifications on a certain product from Novo Nordisk? If the answer to this is yes, then you may have to link up with the company’s headquarters to get someone to attend to your queries. It is to this end I have decided to share the relevant information in this article with you.
Ways to Contact Novo Nordisk Corporate Headquarters
Address: You can send a letter relaying your message(s) to the corporate headquarters mailing address at 800 Scudders Mill Rd, Plainsboro Township, NJ 08536, United States – a visit may also suffice, by the way.
Phone Number: Optionally, you can pick up your phone right about now and dial +1 609-987-5800 to speak with an executive at the headquarters.
Email: Again, you can reach out through email via kiau@novonordisk.com
Novo Nordisk Headquarters Info & Photos
Let me quickly state here that the global headquarters of Novo Nordisk is in Denmark, but the focus in this write-up is the headquarters in the US – which ultimately serves [as the headquarters] for the North American region.
The operations around the headquarters in the US were spread over four different office locations before the company integrated the functions into a single (office) space in Plainsboro. This happened after the massive renovation – costing around US$215 million – of an old building that was previously used by BlackRock. The building was acquired on a 15-year lease, with an expansion right that could see Novo Nordisk staying in the building until 2031.
Novo Nordisk contracted the teams from property development firms including LCOR Inc., Ivy Equities, and Intercontinental Real Estate Corporation to oversee the project while Pennsylvania-based architectural firm, Granum A/I was engaged to design the interior design – even though HOK Group Inc. is the architect of record. The 770,000 square feet building, which is contained within a 64-acre land space, can conveniently accommodate a staff strength of around 1,500 employees.
Novo Nordisk American headquarters is a class A building with LEED Silver certification, and reflects has noticeable innovativeness and modernistic outlook. It has not only been built as a space with many functional areas but also designed to promote and/or sustain the wellbeing of the employees while working. The headquarters features open offices, private offices, conference rooms, workspaces, café, special project rooms, and other functional spaces.
Novo Nordisk Headquarters List
S. No. |
Country |
Address |
---|---|---|
1 |
Canada |
101-2476 Argentia Road Mississauga, Ontario L5N 6M1 |
2 |
Austria |
DC Tower, Donau-City-Str. 7, 1220 Vienna |
3 |
United Arab Emirates |
Novo Nordisk, One Central, The Offices 2 PO Box 505052, Level 2 – Office No: 2.08, 204,205 Dubai World Trade Centre Dubai, United Arab Emirates |
4 |
Australia |
Level 3, 21 Solent Circuit Baulkham Hills |
5 |
India |
Plot No.32, 47-50, EPIP Area, Whitefield Bengaluru 560 066 |
Novo Nordisk Headquarters Executive Team
Lars Fruergaard Jørgensen
President and Chief Executive Officer
Lars began his stint at Novo Nordisk in the Finance Department after joining in 1994 and has been promoted to various management positions to oversee different functions which have excelled at. As the CEO, he drives the company towards the actualization of its goals and objectives, ensuring a credible and efficient corporate is in place to guarantee functional stability at the global scale.
Maziar Mike Doustdar,
Executive vice president and head of International Operations
Maziar is a veteran at Novo Nordisk, the company he has spent virtually his whole professional career beginning from the position of an office clerk in 1992 to become the EVP in charge of International Operations in 2016. Maziar oversees the international operations of Novo Nordisk, making sure that strategies are implemented to promote sustainable performance.
Name | Title |
---|---|
Karsten Munk Knudsen | Executive vice president chief financial officer (CFO). |
Doug Langa | Executive vice president North America Operations. |
Martin Holst Lange | Executive vice president Development. |
David Moore | Executive vice president Corporate Development |
Tania Sabroe | Executive vice president Global People & Organisation |
Marcus Schindler | Executive vice president Research & Early Development and chief scientific officer (CSO). |
Camilla Sylvest | Executive vice president Commercial Strategy & Corporate Affairs. |
Henrik Wulff | Executive vice president Product Supply Quality & IT. |
About Novo Nordisk
History
Novo Nordisk was established in December 1922 as “Nordisk Insulinlaboratorium”. This was after Medicine/Physiology Nobel Laureate, August Krogh – who founded the company alongside Hans Christian Hagedon and August Kongsted – had visited Canada and the University of Toronto [to be specific] where he met the trio of Frederick Banting, Charles Best, and John MacLeod who had succeeded in producing active insulin.
Having obtained permission from the scientists, he moved on to establish the company with the view of manufacturing the product for scientific and humanitarian reasons. The first insulin product from the stable of Novo Nordisk was called ‘Leo’ and it gave mixed results when used on patients. The company however advanced its reputation through the production of highly effective insulin products derived from extensive research and development.
A significant twist in the existence of the company came about in 1924, with the establishment of Novo Terapeutisk Laboratorium – a rival company – by two brothers, Thorvald and Harald Pedersen who had previously worked for Nordisk Insulinlaboratorium. The two companies however merged over six decades later and settled for the name, ‘Novo Nordisk’. The merger eventually made the company the largest manufacturer of insulin in the world – a position that it maintains till this day.
Novo Nordisk would then spin off its enzymes business, Novozymes A/S in the year 2000, and was left with the arm concerned with health care with the name (Novo Nordisk) retained. On the back of this, was the creation of Novo A/S as a wholly-owned subsidiary. In 2003, Novo Nordisk acquired Danish pharmaceutical and life sciences firm, Xellia ApS in a deal worth US$700 million.
Services
Novo Nordisk manufactures and sells pharmaceutical products, particularly those used in the treatment/management of diabetes – there are also products formulated or designed for hormone replacement therapy, hemophilia, and obesity. A wide range of products is made available through eleven different brands.
Besides the direct marketing activities, Novo Nordisk also engages in other functions. For instance, the company has often funded healthcare centers dedicated to the treatment of diabetes in developing nations. Novo Nordisk has also been involved in other projects directed at addressing raising awareness about diabetes, as well as improving treatment outcomes.
Facts
- Novo Nordisk products have a global reach, with more than 32 million individuals using one or more of their products. The company manufactures around 50% of the insulin utilized by diabetes patients on a global scale.
- The World Diabetes Foundation is the brainchild of Novo Nordisk.
- The company has research and discovery centers across five different countries – the US, UK, Denmark, India, and China.